Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-lipoic Acid in Schizophrenia
NCT03788759Phase 3Completed
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpha-lipoic acid in schizophrenia (2 arms). Primary endpoint: Brief Psychiatry Rating Scale at 16 weeks. Started Sep 2019; status: completed.
02
Drugs
alpha-lipoic acid
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03788759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03788759.